Figure 2.

Comparison of survival outcomes. (a, b) The Kaplan‐Meier analysis (a) and paired comparison (b) of PFS of low‐dose decitabine‐primed chemoimmunotherapy, comparing favorably to the best previous PFS of the corresponding therapy. (c) Compared to pre‐resistant PFS of unprimed chemoimmunotherapy, PFS was prolonged by D‐C+CIK cell regimen but not the D‐C regimen. (d) Kaplan‐Meier analysis and log‐rank comparison of PFS and OS by the treatment cohort. (e) For patients in D‐C+CIK cell cohort, the PFS of patients with relapsed cancers was significantly longer than with refractory patiens. (f) The D‐C regimen prolonged the PFS of patients received more cycles of treatment. Abbreviations: Pre‐PFS, pre‐resistant PFS of the corresponding chemoimmunotherapy; PFS, PFS of low‐dose decitabine‐primed chemoimmunotherapy. [Color figure can be viewed at http://wileyonlinelibrary.com]